We are live on ! Find out more
AVTX icon

Avalo Therapeutics

53 hedge funds and large institutions have $131M invested in Avalo Therapeutics in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 11

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 52 → 53 (+1)

6% more capital inflows, than outflows

Capital inflows: $3.49M | Capital outflows: $3.31M

0.09% more ownership

Funds ownership: 66.42% → 66.5% (+0.09%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
53
Holders Change
+1
Holders Change %
+1.92%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
21
Reduced
11
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AVTX Hedge Fund Activity: Q4 2020 in Review

53 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2020, worth a combined $131M — up 16% from $113M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AVTX positions and 6 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $1.06M. The largest seller was Opaleye Management, cutting an estimated $1.81M.

  • 53 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2020, up from 52 in Q3 2020.
  • Funds reported $131M of Avalo Therapeutics stock for Q4 2020, up 16% quarter-over-quarter.
  • 7 funds opened new Avalo Therapeutics positions in Q4 2020 and 6 closed out, a net change of +1 holder.
  • The largest Avalo Therapeutics buyer in Q4 2020 was Nantahala Capital Management, an estimated $1.06M added.
  • The largest Avalo Therapeutics seller in Q4 2020 was Opaleye Management, an estimated $1.81M sold.

Based on aggregated 13F filings for Q4 2020.